These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. A comparison of anxiety symptoms and correlates of anxiety in people with progressive and relapsing-remitting multiple sclerosis. Knowles LM; Tingey JL; Newman AK; von Geldern G; Alschuler KN Mult Scler Relat Disord; 2022 Jul; 63():103918. PubMed ID: 35700673 [TBL] [Abstract][Full Text] [Related]
12. Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis. Sato S; Lim J; Miehm JD; Buonaccorsi J; Rajala C; Khalighinejad F; Ionete C; Kent JA; van Emmerik REA Mult Scler Relat Disord; 2020 Jun; 41():102031. PubMed ID: 32172213 [TBL] [Abstract][Full Text] [Related]
13. Ocrelizumab in highly disabled progressive multiple sclerosis patients. Houtchens M; Howard D Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693 [TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand'Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; McCombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Castillo-Triviño ; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Oreja-Guevara ; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H J Med Econ; 2024; 27(1):109-125. PubMed ID: 38085684 [TBL] [Abstract][Full Text] [Related]
15. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis. Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010 [TBL] [Abstract][Full Text] [Related]
17. Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study. Zeineddine M; Al-Hajje A; Salameh P; Massouh J; Saab G; Al-Roughani R; Ahmed SF; Al-Mahdawi A; Shalaby N; Inshasi J; Sahraian MA; Gouider R; Mrabet S; Al-Khabouri J; Shayganneja V; Chentouf A; Boumediene F; Yamout B Mult Scler Relat Disord; 2024 Oct; 90():105790. PubMed ID: 39121598 [TBL] [Abstract][Full Text] [Related]
18. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T; CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228 [TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study. Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]